| Date | Event | Description | 
|---|---|---|
| 3 September 2014 | Amended | Final sentence in paragraph three under 'Effects of interventions > Comparisons showing vaccines' efficacy' section has been amended. The value of NNV reported in the text (NNV = 28) was incorrect. It has been corrected to NNV = 2.8. | 
| 21 June 2012 | Feedback has been incorporated | Feedback comment and reply added to the review | 
| 16 November 2011 | New search has been performed | For this 2011 update we included the following 15 new trials and datasets (aa Bracco Neto 2009a; aa Bracco Neto 2009b); (ba Cochran 2010a; ba Cochran 2010b; ba Cochran 2010c); (ba Eisenberg 2008a; ba Eisenberg 2008b); ba Gilca 2011; ba Kelly 2011; ba Kissling 2011; ba Mahmud 2011; ab Mallory 2010; ca Ortqvist 2011; ab Plennevaux 2011; (ba Staat 2011a; ba Staat 2011b); ba Valenciano 2011; ba Van Buynder 2010; ca Yin 2011; cb MPA 2011. Readers are reminded that one study may provide multiple datasets (i.e. Bracco Neto 2009 a and b) We excluded the following trials Ambrose 2011; Belshe 2008; Fujieda 2008; Haba‐Rubio 2011; Jansen 2008; Kissling 2011a; McMahon 2008; Muhammad 2011; Stowe 2011; Wu 2010 | 
| 16 November 2011 | New citation required but conclusions have not changed | A new author joined the team to update this review | 
| 4 February 2008 | New search has been performed | For the 2007 update we reran the searches and identified 1090 possible titles of interest. We retrieved 15 and excluded 5: Neuzil 2006, Hambidge 2006, France 2004 because they were non comparative, Daubeney 1997 because it had not been carried out in healthy children and Ghendon 2004 because it assessed the impact of vaccinating children to prevent influenza in the elderly. We included 10 studies. Two were placebo controlled trials of cold adapted live attenuated influenza vaccine (CAIV) (Tam 2007, Vesikari 2006), two (Anonymous 2005, Goodman 2006) were case‐control studies assessing respectively the efficacy and safety of TIV, three were prospective cohort studies assessing the effectiveness of respectively CAIV (Wiggs‐Stayner 2006), virosomal vaccine (Salleras 2006) and TIV vaccines (Fujieda 2006) and one was a retrospective cohort study (Allison 2006) assessing effectiveness of an undescribed vaccine. Two more studies included were a prospective cohort study reporting effectiveness and safety of CAIV in school‐aged children (King 2006) and prospective single blind cohort study assessing effectiveness of TIV against OM (Ozgur 2006). Our conclusions remain unchanged. | 
| 15 January 2008 | Amended | Converted to new review format. | 
| 10 November 2007 | New citation required and conclusions have changed | Substantive amendment |